questionsmedicales.fr
Phénomènes physiques
Rayonnement
Rayonnement non ionisant
Son (physique)
Son (physique) : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Perte auditive
Audiométrie
Troubles auditifs
Tympanométrie
Infection de l'oreille
Otite
Acouphènes
Évaluation auditive
Symptômes auditifs
Examen auditif
Symptômes
5
Acouphènes
Symptômes auditifs
Infection de l'oreille
Otite
Exposition au bruit
Fatigue auditive
Prévention
5
Prévention
Perte auditive
Infection de l'oreille
Prévention
Milieu bruyant
Protection auditive
Traumatismes auditifs
Prévention
Traitements
5
Perte auditive
Appareils auditifs
Acouphènes
Thérapie sonore
Exposition au bruit
Protection auditive
Troubles auditifs
Corticostéroïdes
Complications
5
Perte auditive
Complications
Perte auditive
Qualité de vie
Facteurs de risque
5
Perte auditive
Facteurs de risque
Acouphènes
Facteurs de risque
Mode de vie
Santé auditive
Médicaments
Effets secondaires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Son (physique) : Questions médicales les plus fréquentes",
"headline": "Son (physique) : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Son (physique) : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-28",
"dateModified": "2025-03-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Son (physique)"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Rayonnement non ionisant",
"url": "https://questionsmedicales.fr/mesh/D011840",
"about": {
"@type": "MedicalCondition",
"name": "Rayonnement non ionisant",
"code": {
"@type": "MedicalCode",
"code": "D011840",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G01.750.770"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Phonons",
"alternateName": "Phonons",
"url": "https://questionsmedicales.fr/mesh/D060739",
"about": {
"@type": "MedicalCondition",
"name": "Phonons",
"code": {
"@type": "MedicalCode",
"code": "D060739",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G01.750.770.776.783"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ondes ultrasonores",
"alternateName": "Ultrasonic Waves",
"url": "https://questionsmedicales.fr/mesh/D000069453",
"about": {
"@type": "MedicalCondition",
"name": "Ondes ultrasonores",
"code": {
"@type": "MedicalCode",
"code": "D000069453",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G01.750.770.776.891"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Ondes de choc de haute énergie",
"alternateName": "High-Energy Shock Waves",
"url": "https://questionsmedicales.fr/mesh/D019220",
"about": {
"@type": "MedicalCondition",
"name": "Ondes de choc de haute énergie",
"code": {
"@type": "MedicalCode",
"code": "D019220",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G01.750.770.776.891.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Son (physique)",
"alternateName": "Sound",
"code": {
"@type": "MedicalCode",
"code": "D013016",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Laurel J Trainor",
"url": "https://questionsmedicales.fr/author/Laurel%20J%20Trainor",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology, Neuroscience and Behaviour, McMaster University, Hamilton, Ontario, Canada."
}
},
{
"@type": "Person",
"name": "Akihiro Funamizu",
"url": "https://questionsmedicales.fr/author/Akihiro%20Funamizu",
"affiliation": {
"@type": "Organization",
"name": "Cold Spring Harbor Laboratory, 1 Bungtown Rd, Cold Spring Harbor, NY 11724, USA."
}
},
{
"@type": "Person",
"name": "Fred Marbach",
"url": "https://questionsmedicales.fr/author/Fred%20Marbach",
"affiliation": {
"@type": "Organization",
"name": "Cold Spring Harbor Laboratory, 1 Bungtown Rd, Cold Spring Harbor, NY 11724, USA."
}
},
{
"@type": "Person",
"name": "Anthony M Zador",
"url": "https://questionsmedicales.fr/author/Anthony%20M%20Zador",
"affiliation": {
"@type": "Organization",
"name": "Cold Spring Harbor Laboratory, 1 Bungtown Rd, Cold Spring Harbor, NY 11724, USA."
}
},
{
"@type": "Person",
"name": "Adib Mehrabi",
"url": "https://questionsmedicales.fr/author/Adib%20Mehrabi",
"affiliation": {
"@type": "Organization",
"name": "Department of Linguistics, Queen Mary University of London, London, England."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Imatinib mesylate-induced acute hepatotoxicity.",
"datePublished": "2023-07-18",
"url": "https://questionsmedicales.fr/article/37464887",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10781552231188307"
}
},
{
"@type": "ScholarlyArticle",
"name": "Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate.",
"datePublished": "2022-08-08",
"url": "https://questionsmedicales.fr/article/35898161",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/dth.15736"
}
},
{
"@type": "ScholarlyArticle",
"name": "Non-Hodgkin's lymphoma developed during imatinib mesylate treatment of chronic myeloid leukemia.",
"datePublished": "2022-11-07",
"url": "https://questionsmedicales.fr/article/36344191",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10781552221137700"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative photo-oxidative degradation of etodolac, febuxostat and imatinib mesylate by UV-C/H",
"datePublished": "2022-05-13",
"url": "https://questionsmedicales.fr/article/35569533",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.envres.2022.113385"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of Imatinib Mesylate on Growth in Pediatric Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.",
"datePublished": "2023-03-17",
"url": "https://questionsmedicales.fr/article/37027248",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MPH.0000000000002660"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes physiques",
"item": "https://questionsmedicales.fr/mesh/D055585"
},
{
"@type": "ListItem",
"position": 3,
"name": "Rayonnement",
"item": "https://questionsmedicales.fr/mesh/D011827"
},
{
"@type": "ListItem",
"position": 4,
"name": "Rayonnement non ionisant",
"item": "https://questionsmedicales.fr/mesh/D011840"
},
{
"@type": "ListItem",
"position": 5,
"name": "Son (physique)",
"item": "https://questionsmedicales.fr/mesh/D013016"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Son (physique) - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Son (physique)",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Son (physique)",
"description": "Comment évaluer la perte auditive ?\nQuels tests pour les troubles auditifs ?\nQuels signes indiquent une infection de l'oreille ?\nComment détecter les acouphènes ?\nQuels symptômes nécessitent un examen auditif ?",
"url": "https://questionsmedicales.fr/mesh/D013016?mesh_terms=Imatinib+Mesylate#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Son (physique)",
"description": "Quels sont les symptômes d'une perte auditive ?\nComment se manifestent les acouphènes ?\nQuels signes d'infection de l'oreille ?\nQuels symptômes d'une exposition au bruit ?\nComment reconnaître une otite ?",
"url": "https://questionsmedicales.fr/mesh/D013016?mesh_terms=Imatinib+Mesylate#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Son (physique)",
"description": "Comment prévenir la perte auditive ?\nQuelles mesures pour éviter les infections de l'oreille ?\nComment réduire le risque d'acouphènes ?\nQuelles précautions en milieu bruyant ?\nComment éviter les traumatismes auditifs ?",
"url": "https://questionsmedicales.fr/mesh/D013016?mesh_terms=Imatinib+Mesylate#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Son (physique)",
"description": "Quels traitements pour la perte auditive ?\nComment traiter les acouphènes ?\nQuel traitement pour l'otite ?\nComment gérer l'exposition au bruit ?\nQuels médicaments pour les troubles auditifs ?",
"url": "https://questionsmedicales.fr/mesh/D013016?mesh_terms=Imatinib+Mesylate#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Son (physique)",
"description": "Quelles complications de la perte auditive ?\nQuels risques liés aux acouphènes ?\nQuelles complications d'une otite non traitée ?\nQuels effets du bruit sur la santé ?\nComment la perte auditive affecte-t-elle la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D013016?mesh_terms=Imatinib+Mesylate#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Son (physique)",
"description": "Quels facteurs augmentent le risque de perte auditive ?\nQuels sont les facteurs de risque d'acouphènes ?\nQuelles conditions augmentent le risque d'otite ?\nComment le mode de vie influence-t-il l'audition ?\nQuels médicaments peuvent affecter l'audition ?",
"url": "https://questionsmedicales.fr/mesh/D013016?mesh_terms=Imatinib+Mesylate#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer la perte auditive ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un audiogramme mesure la capacité auditive à différentes fréquences."
}
},
{
"@type": "Question",
"name": "Quels tests pour les troubles auditifs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme la tympanométrie et l'audiométrie sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une infection de l'oreille ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Douleur, écoulement et perte auditive peuvent signaler une infection."
}
},
{
"@type": "Question",
"name": "Comment détecter les acouphènes ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un examen auditif et des questionnaires évaluent la présence d'acouphènes."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent un examen auditif ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des difficultés à entendre, des bourdonnements ou des douleurs doivent être examinées."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une perte auditive ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Difficulté à comprendre la parole, besoin d'augmenter le volume, isolement social."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les acouphènes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils se présentent comme des bourdonnements ou des sifflements dans l'oreille."
}
},
{
"@type": "Question",
"name": "Quels signes d'infection de l'oreille ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Douleur, fièvre, écoulement et irritabilité chez les enfants."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une exposition au bruit ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Sensation de pression dans les oreilles, fatigue auditive, acouphènes temporaires."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une otite ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Douleur intense, rougeur de l'oreille, parfois fièvre et irritabilité."
}
},
{
"@type": "Question",
"name": "Comment prévenir la perte auditive ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les bruits forts, utiliser des protections auditives et faire des bilans réguliers."
}
},
{
"@type": "Question",
"name": "Quelles mesures pour éviter les infections de l'oreille ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir une bonne hygiène, éviter la fumée de tabac et vacciner les enfants."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque d'acouphènes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Limiter l'exposition au bruit et gérer le stress peuvent aider à prévenir les acouphènes."
}
},
{
"@type": "Question",
"name": "Quelles précautions en milieu bruyant ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Porter des bouchons d'oreilles et réduire le temps d'exposition au bruit intense."
}
},
{
"@type": "Question",
"name": "Comment éviter les traumatismes auditifs ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les sons soudains et utiliser des équipements de protection lors d'activités bruyantes."
}
},
{
"@type": "Question",
"name": "Quels traitements pour la perte auditive ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les appareils auditifs, les implants cochléaires et la rééducation auditive sont utilisés."
}
},
{
"@type": "Question",
"name": "Comment traiter les acouphènes ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies sonores, des conseils et des médicaments peuvent aider à gérer les acouphènes."
}
},
{
"@type": "Question",
"name": "Quel traitement pour l'otite ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Antibiotiques pour les infections bactériennes, analgésiques pour la douleur."
}
},
{
"@type": "Question",
"name": "Comment gérer l'exposition au bruit ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des protections auditives et limiter le temps d'exposition au bruit fort."
}
},
{
"@type": "Question",
"name": "Quels médicaments pour les troubles auditifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des corticostéroïdes peuvent être prescrits pour réduire l'inflammation de l'oreille."
}
},
{
"@type": "Question",
"name": "Quelles complications de la perte auditive ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Isolement social, dépression et difficultés de communication peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels risques liés aux acouphènes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les acouphènes peuvent entraîner de l'anxiété, des troubles du sommeil et de la concentration."
}
},
{
"@type": "Question",
"name": "Quelles complications d'une otite non traitée ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Infections chroniques, perte auditive permanente et complications intracrâniennes possibles."
}
},
{
"@type": "Question",
"name": "Quels effets du bruit sur la santé ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le bruit excessif peut causer des troubles auditifs, du stress et des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment la perte auditive affecte-t-elle la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire l'interaction sociale, affecter l'emploi et diminuer la qualité de vie globale."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de perte auditive ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exposition au bruit, l'âge, les antécédents familiaux et certaines maladies augmentent le risque."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'acouphènes ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exposition au bruit, le stress, l'âge et certaines conditions médicales peuvent contribuer."
}
},
{
"@type": "Question",
"name": "Quelles conditions augmentent le risque d'otite ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les allergies, les infections respiratoires et l'exposition à la fumée de tabac sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie influence-t-il l'audition ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, sans tabac et avec une alimentation équilibrée, peut protéger l'audition."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent affecter l'audition ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains antibiotiques et médicaments anti-inflammatoires peuvent causer des effets secondaires auditifs."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 25/03/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Psychology, Neuroscience and Behaviour, McMaster University, Hamilton, Ontario, Canada.
McMaster Institute for Music and the Mind, McMaster University, Hamilton, Ontario, Canada.
Rotman Research Institute, Baycrest Hospital, Toronto, Ontario, Canada.
Publications dans "Son (physique)" :
2 publications dans cette catégorie
Affiliations :
Cold Spring Harbor Laboratory, 1 Bungtown Rd, Cold Spring Harbor, NY 11724, USA.
Present address: Institute for Quantitative Biosciences, the University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 1130032, Japan.
Present address: Department of Life Sciences, Graduate School of Arts and Sciences, the University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo, 1538902, Japan.
Publications dans "Son (physique)" :
2 publications dans cette catégorie
Affiliations :
Cold Spring Harbor Laboratory, 1 Bungtown Rd, Cold Spring Harbor, NY 11724, USA.
Present address: The Francis Crick Institute, 1 Midland Rd, NW1 4AT London, UK.
Publications dans "Son (physique)" :
2 publications dans cette catégorie
Affiliations :
Cold Spring Harbor Laboratory, 1 Bungtown Rd, Cold Spring Harbor, NY 11724, USA.
Publications dans "Son (physique)" :
2 publications dans cette catégorie
Affiliations :
Department of Linguistics, Queen Mary University of London, London, England.
School of Electronic Engineering and Computer Science, Queen Mary University of London, London, England.
Publications dans "Son (physique)" :
2 publications dans cette catégorie
Affiliations :
Department of Linguistics, Queen Mary University of London, London, England.
Publications dans "Son (physique)" :
2 publications dans cette catégorie
Affiliations :
Department of Linguistics, Queen Mary University of London, London, England.
Publications dans "Son (physique)" :
2 publications dans cette catégorie
Affiliations :
Food Quality Perception & Society Team, iSENSE Lab, Department of Food Science, Aarhus University, Aarhus, Denmark; Sino-Danish College (SDC), University of Chinese Academy of Sciences, Beijing, China.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
Department of Psychology, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA.
Center for the Neural Basis of Cognition, Pittsburgh, Pennsylvania 15213, USAuoszczap@andrew.cmu.edu, hellerl@andrew.cmu.edu, seojunj@andrew.cmu.edu, banance@andrew.cmu.edu.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
Department of Psychology, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA.
Center for the Neural Basis of Cognition, Pittsburgh, Pennsylvania 15213, USAuoszczap@andrew.cmu.edu, hellerl@andrew.cmu.edu, seojunj@andrew.cmu.edu, banance@andrew.cmu.edu.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
Department of Psychology, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
Department of Psychology, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
Consultant Neurologist & Honorary Clinical Associate Professor of Neurology, Department of Neurology, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK. Electronic address: melissamaguire@nhs.net.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
International Islamic University Malaysia, Kulliyyah of Allied Health Sciences, Department of Audiology and Speech Language Pathology, Kuantan, Pahang, Malaysia.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
International Islamic University Malaysia, Kulliyyah of Allied Health Sciences, Department of Audiology and Speech Language Pathology, Kuantan, Pahang, Malaysia. sarahrahmat@iium.edu.my.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
International Islamic University Malaysia, Kulliyyah of Allied Health Sciences, Department of Audiology and Speech Language Pathology, Kuantan, Pahang, Malaysia.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
Universiti Kebangsaan Malaysia, Faculty of Health Sciences, Centre for Rehabilitation and Special Needs Studies, Kuala Lumpur, Malaysia.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
Universiti Kebangsaan Malaysia, Faculty of Health Sciences, Centre for Rehabilitation and Special Needs Studies, Kuala Lumpur, Malaysia.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
International Islamic University Malaysia, Kulliyyah of Allied Health Sciences, Department of Optometry and Visual Sciences, Kuantan, Pahang, Malaysia.
Publications dans "Son (physique)" :
1 publication dans cette catégorie
Affiliations :
Department of Fish and Wildlife Science, Oregon State University, Corvallis, Oregon 97331, USA.
Publications dans "Son (physique)" :
Imatinib is a first-line selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia. Although imatinib-induced hepatotoxicity may aggravate the patient's clinical condition...
We report a 51-year-old man, suffering from acute toxic hepatitis after 5 months of imatinib treatment for chronic myeloid leukemia....
The outcome was favorable after discontinuation of treatment with normalization of biological liver function after 12 weeks. The treatment was switched to nilotinib without any incidents....
Regular liver function test monitoring is recommended during imatinib treatment. In fact of acute hepatic toxicity, treatment with imatinib should be stopped in the case of cytolysis more than five ti...
Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor characterized by a high risk of local recurrence but a low risk of metastasis. A small subpopulation of DFSP undergoes fibrosarcomato...
Non-Hodgkin lymphoma induced by imatinib, as a tyrosine kinase inhibitor, is a rare complication....
A 54-year-old female with a history of chronic myeloid leukemia (CML) was treated with imatinib as first-line therapy. The patient achieved a profound molecular response with treatment-free remission ...
Imatinib was discontinued. The lymphoma was treated with rituximab and chemotherapy....
Non-Hodgkin's lymphoma is a rare side effect of tyrosine kinase inhibitors and highlights the importance of follow-up CML patients....
The pharmaceutical contamination in aquatic environment has arisen increasing concern due to its potentially chronic toxicity. In recent years, HO° and SO...
The outcomes of pediatric chronic myeloid leukemia (CML) have improved with the use of imatinib mesylate (IM). Multiple reports of growth deceleration with IM have raised concerns, necessitating caref...
In this work, the rapid, facile, and eco-friendly green process was introduced in the preparation of β-cyclodextrin/magnetic iron oxide nanoparticles by using the aqueous Mentha longifolia extracts of...
An intraarticular, liposphere-based, formulation of Imatinib mesylate for weekly administration was developed. Lipospheres were prepared using double emulsion technique using dierucoyl phosphatidylcho...
The receptor tyrosine kinase inhibitor imatinib improves patient cancer survival but is linked to cardiotoxicity. This study investigated imatinib's effects on cell viability, apoptosis, autophagy, an...
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the Philadelphia (Ph) chromosome. After the introduction of imatinib mesylate (IM) in 2000, the natural history ...
To evaluate the molecular response (MR) in patients with chronic-phase CML (CML-CP) not included in clinical studies and correlate them with the responses obtained in clinical trials....
Between January 2007 and January 2017, 227 patients newly diagnosed with CML-CP treated with IM as first-line treatment were included. This study is an observational, retrospective, and single-center ...
At a median follow-up time of 7.3 years, 60.3% of the 227 patients who started IM were still on IM. Early molecular response (EMR) at 3 and 6 months was achieved by 74.2% and 65%, respectively. The me...
The results presented are similar to those described in prospective and randomized trials, demonstrating that the outcomes are reproducible in the real world. EMR at 3 and 6 months reflects better lon...
Chronic Myeloid Leukemia (CML) is a hematologic neoplasia, characterized as a proliferative disease of the hematopoietic system. Imatinib mesylate (IM), a selective tyrosine kinase inhibitor, is consi...